Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Ann Rheum Dis. 2018 Jan 23;77(5):714–719. doi: 10.1136/annrheumdis-2017-212436

Table 1. Prevalence of anti-NT5C1A in the sera of pediatric patients.

Total (n=502)
% (N)
Juvenile myositis (n=380) 27% (102) **
 Juvenile Dermatomyositis (n= 307) 27% (83) **
 Juvenile Polymyositis (n= 27) 11% (3)
 Juvenile myositis overlap syndromes (n=46) 35% (16) **
  Juvenile myositis overlapping with Juvenile systemic lupus erythematosus (n=14) 36% (5) *
  Juvenile myositis overlapping with Juvenile systemic sclerosis (n=11) 27% (3)
  Juvenile myositis overlapping with Juvenile idiopathic arthritis (n=7) 14% (1)
  Juvenile myositis overlapping with other pediatric autoimmune diagnosis (n=14) 50% (7) **
Juvenile idiopathic arthritis (n=30) 27% (8) *
Healthy pediatric controls (n=92) 12% (11)
*

<0.05;

**

<0.01;

***

<0.001

%= percentage positive for anti-NT5C1A autoantibodies, N=number of sera testing positive for anti-NT5C1A autoantibodies.